Eron Kelly, CEO of ConcertAI, and Dr. Shaalan Beg, CMO, oncology, ConcertAI, discuss how AI can help physicians access the right information at the right time while supporting clinical trials, research, and quality initiatives.
News|Articles|September 22, 2026
Characterizing LNPs: Meeting Regulatory Expectations With FFF-MALS
Author(s)Waters Corporation
This executive summary examines how field-flow fractionation coupled with multi-angle light scattering (FFF-MALS) characterizes lipid nanoparticles (LNPs) as regulatory expectations from FDA, EMA, and USP converge on a shared set of critical quality attributes. It walks through how FFF-MALS resolves particle size, molar mass, and payload distribution in a single non-destructive run, and includes a case study comparing two authorized mRNA vaccines. Readers will see how size-resolved analysis uncovered differences in payload distribution that bulk-average methods missed.
Related to this article
Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
Biocon's Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, has become the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA's newly adopted tailored clinical approach, which can reduce comparative efficacy trial requirements.
Novo Nordisk reports that CagriSema outperformed tirzepatide with 12.4% weight loss versus 9.1% in a phase 3 trial in adults with type 2 diabetes.
Vironexis Biotherapeutics reported that the first three antibody-naive patients with relapsed/refractory acute lymphoblastic leukemia treated with its one-time in vivo immunotherapy VNX-101 all achieved MRD-negative complete responses, with durability tracked through at least nine months.
New data show risk-based and centralized monitoring shifts effort across roles, sites, and timelines, reshaping how sponsors plan CRA capacity needs.
Laru-zova helped 31% of high-dose patients gain 15+ letters of vision, representing the first pivotal trial to succeed in treating XLRP.
Telix will acquire ITM for $1.65 billion, gaining a phase 3-validated therapy that cut GEP-NET progression risk versus everolimus.